A case of gastric malignant lymphoma markedly responding to chronic daily and oral administration of low-dose etoposide
Moriya, A.; Ikeda, A.; Yokoyama, N.; Yokoyama, T.; Abe, Y.; Miyamoto, K.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(14): 2229-2233
1993
ISSN/ISBN: 0385-0684 PMID: 8239691 Document Number: 420786
A 71-year-old woman was diagnosed as malignant lymphoma (non-Hodgkin's lymphoma, diffused mixed cell type) which involved gastric lesions. Combined chemotherapies were undertaken using VCR, CPA, 4-epi-ADM and PRED and then etoposide, 4-epi-ADM and PRED. After about 5 months, recurrent lesions were revealed in the right supraclavicular lymph node, so we conducted additional chemotherapy. However, the patient rejected intravenous therapy and required out-patient therapy, so daily oral administration of etoposide (50 mg/day) was carried out. Because of the toxicities of alopecia, the dose was reduced to 50 mg every other day, then to 25 mg every other day. No recurrent signs have been seen for the past 3 years. Bone marrow suppression was little. Chronic oral administration of low-dose etoposide is the potential salvage therapy of gastric malignant lymphoma.